1. Introduction {#sec1-molecules-22-00828}
===============

*Nicandra physaloides* (L.) Gaertn (Solanaceae) was recorded in the Dictionary of Medicinal Plants \[[@B1-molecules-22-00828]\], as being an annual herb of monotypic genus, sweet and acerbity, bitter and natural in flavor, which possessed the various effects of sedation, eliminating phlegm, heat-clearing and detoxifying. Modern researchers have indicated that *Nicandra physaloides* was reported being taken as analgesic, vermifuge, antibacterial agent, antipyretic, diuretic and mydriatic \[[@B2-molecules-22-00828],[@B3-molecules-22-00828],[@B4-molecules-22-00828]\] and applied to the treatments of hydrophobia, psychosis, epilepsy, rheumatoid arthritis, nasosinusitis, influenza, urinary tract infection, sore and furuncle \[[@B5-molecules-22-00828],[@B6-molecules-22-00828]\]. Meanwhile, it was used in folk medicine for sedation, eliminating phlegm, heat-clearing and detoxifying. Equally important, the Chinese Herbal Medicine Anthology of Yun Nan recorded that the fruits of *Nicandra physaloides* (L.) Gaertn possessed the effects of dispelling wind and anti-inflammation. However, the effective material basic was unclear and indistinct \[[@B7-molecules-22-00828],[@B8-molecules-22-00828]\]. As a part of our ongoing research on structurally diverse and anti-inflammatory ingredients from *Nicandra physaloides*, our study led to the isolation of three new compounds, Nicglycoside A--C (**1**--**3**), along with fifteen known ones including benzyl α-[l]{.smallcaps}-arabinopyranosyl-(1→6)-β-[d]{.smallcaps}-glucopyranoside (**4**) \[[@B9-molecules-22-00828]\], 6-*O*-[l]{.smallcaps}-arabinopyranosyl-β-[d]{.smallcaps}-glucopyr-anoside (**5**) \[[@B10-molecules-22-00828]\], 2-Phenylethyl-β-[d]{.smallcaps}-glucopyranoside (**6**) \[[@B11-molecules-22-00828]\], (+)-phenylethyl-8-*O*-α-[l]{.smallcaps}-rhamnopyr-anoside (**7**) \[[@B12-molecules-22-00828],[@B13-molecules-22-00828]\], Salidroside (4-hydroxy-2-Phenylethyl-*O*-β-[d]{.smallcaps}-glucopyranoside, **8**) \[[@B14-molecules-22-00828]\], phenethanol-β-[d]{.smallcaps}-gentiobioside (**9**) \[[@B15-molecules-22-00828]\], Forsythoside E (3,4-dihydroxyl-2-Phenylethyl-*O*-β-[l]{.smallcaps}-arabinopyranosyl-(1→6)-β-[d]{.smallcaps}-glucopyranoside, **10**) \[[@B16-molecules-22-00828]\], and phenethylalcohol 8-*O*-β-[d]{.smallcaps}-glucopyranosyl-(1→2)-\[*O*-α-[l]{.smallcaps}-arabinopyranosyl-(1→6)\]-*O*-β-[d]{.smallcaps}-glucopyranoside (**11**) \[[@B17-molecules-22-00828]\], Helicide (4-β-[d]{.smallcaps}-galactopyranosyloxy-benzaldehyde, **12**) \[[@B18-molecules-22-00828]\], picein (1-\[4-(β-[d]{.smallcaps}-glucopyranosyloxy-)phenyl\]-ethanone, **13**) \[[@B19-molecules-22-00828]\], benzoic acid-β-[d]{.smallcaps}-gentiobioside (**14**) \[[@B14-molecules-22-00828]\], butyl-β-[d]{.smallcaps}-glucopyranoside (**15**) \[[@B20-molecules-22-00828]\], Foliachinenoside I (3-methylbutyl-4-*O*-α-[l]{.smallcaps}-arabinopyranosyl(1→6)-β-[d]{.smallcaps}-glucopyranoside, **16**) \[[@B21-molecules-22-00828]\], (*Z*)-3-Hexenyl-1-*O*-β-[d]{.smallcaps}-glucopyranose (**17**) \[[@B22-molecules-22-00828]\] and (*Z*)-3-hexenyl *O*-α-arabinopyranosyl-(1→6)-*O*-β-[d]{.smallcaps}-glucopyranoside (**18**) \[[@B23-molecules-22-00828]\], respectively ([Figure 1](#molecules-22-00828-f001){ref-type="fig"}, [Table S1](#app1-molecules-22-00828){ref-type="app"}). This article is the first time that the phenyl-glycosides and fat glycosides from the fruits of *Nicandra physaloides* have been studied and reported. Here, the isolation and structural elucidation of compounds **1**--**18**, as well as their anti-inflammatory activities, were elaborated and provided.

2. Results {#sec2-molecules-22-00828}
==========

2.1. Structure Elucidation {#sec2dot1-molecules-22-00828}
--------------------------

Compound **1** possessed the molecular formula of C~19~H~28~O~10~ according to the HR-ESI-MS at *m*/*z* 417.1755 \[M + H\]^+^. The ^1^H-NMR spectrum ([Table 1](#molecules-22-00828-t001){ref-type="table"}) of 1 showed the characteristic signals of mono-substituted benzene ring at δ~H~ 7.24 (4H, overlap, H-2, 3, 5, 6) and 7.16 (m, H-4). In addition, two protons signals of anomeric carbon of β-galactose and α-arabinose were observed at δ~H~ 4.65 (d, *J* = 7.9 Hz, H-1′) and 4.29 (d, *J* = 6.8 Hz, H-1′′), respectively. Combined with the DEPT, ^13^C-NMR spectrum of **1** showed 19 signals, including a group of benzene at δ~C~ 140.2, 130.0 (2 × C), 129.4 (2 × C) and 127.2, two methylene signals at δ~C~ 71.8 and 37.3, and two groups of galactopyranose and arabinopyranose glycosyls at δ~C~ 102.0, 72.3, 72.8, 68.8, 74.5, 69.8 and 105.2, 72.4, 74.2, 69.5, 66.7. The HMBC correlations ([Figure 2](#molecules-22-00828-f002){ref-type="fig"}) between H-1′ and C-8, H-1′′ and C-6′ suggested the attachment position of the galactosyl at C-8 and C-1′′ of arabinose at C-6′ of galactosyl \[[@B24-molecules-22-00828]\]. Assignments of all groups of **1** were achieved by ^1^H-^1^H COSY, HSQC and HMBC ([Figure 2](#molecules-22-00828-f002){ref-type="fig"}). The absolute configuration of the glycosyls group of compound **1** was determined by GC analysis according to the same *t*~R~ at 12.9 and 32.5 min with standard [l]{.smallcaps}-arabinopyranose and [d]{.smallcaps}-galactopyranoside, respectively. From the above data, the structure of **1** was elucidated as 2-phenylethyl *O*-α-[l]{.smallcaps}-arabinopyranosyl-(1→6)-β-[d]{.smallcaps}-galactopyranoside, named Nicglycoside A.

Compound **2** was obtained as an amorphous powder with the molecular formula assigned as C~17~H~30~O~10~ by positive HR-ESI-MS from the \[M + H\]^+^ signal at *m*/*z* 395.1901, indicating 3 degrees of unsaturation The ^1^H-NMR spectrum ([Table 1](#molecules-22-00828-t001){ref-type="table"}) of **2** showed two groups characteristic signals of galactose and arabinose glycosyls at δ~H~ 4.61 (1H, d, *J* = 8.0 Hz, H-1′) and 4.30 (1H, d, *J* = 6.7, H-1′′), which were in accordance with the glycosyl of compound **1**; a pair signals of double bonds δ~H~ 5.42 (2H, m), three methylene at δ~H~ 2.07 (2H, m), 2.37 (2H, m), 3.52(1H, o), 3.84 (1H, o) and one methyl at δ~H~ 0.96 (3H, t, 7.6). In the ^13^C-NMR, the glycosyl signals of galactopyranose and arabinopyranose existed at δ~C~ 102.0, 72.3, 72.8, 68.8, 74.4, 69.8 and 105.2, 72.4, 74.2, 69.5, 66.7. The HMBC correlations ([Figure 2](#molecules-22-00828-f002){ref-type="fig"}) between H-1′ and C-6, H-1′′ and C-6′ suggested the attachment position of the galactosyl was at C-6 and C-6′ of galactosyl was substituted connecting with the C-1′′ of arabinose. Its absolute configurations of the glycosyls group were determined by GC analysis as with the compound **1**. From the above data and combined with the literatures \[[@B24-molecules-22-00828],[@B25-molecules-22-00828]\], the structure of **2** was elucidated as (*Z*)-hex-3-en-1-ol-α-[l]{.smallcaps}-arabinopyranosyl-(1→6)-β-[d]{.smallcaps}-galactopyranoside, named Nicglycoside B.

Compound **3** possessed the molecular formula of C~23~H~40~O~15~ according to the HR-ESI-MS at *m*/*z* 557.2419 \[M + H\]^+^. The ^1^H-NMR spectrum ([Table 1](#molecules-22-00828-t001){ref-type="table"}) of **3** showed three characteristic signals of glycosyls at δ~H~ 4.59 (1H, d, *J* = 7.8 Hz, H-1′), and 4.30 (1H, d, *J* = 6.7, H-1′′), and 4.43 (1H, d, *J* = 7.6, H-1′′′), assigned to glucose, arabinose and glucose, respectively. Moreover, a group of parent nucleus signals existed in accordance with **2** at δ~H~ 5.42 (2H, m), 2.08 (2H, m), 2.36 (2H, m), 3.52 (1H, o), 3.84 (1H, o) and 0.97 (3H, t, 7.6). Combined with the DEPT, ^13^C-NMR spectrum of **3** showed 23 signals, including a fatly chain group, which is the same as compound **2**, at δ~C~ 14.7, 21.6, 134.5, 126.0, 28.8, 70.6, and two groups of glucose and a group of arabinose glycosyls at δ~C~ 105.0, 83.0, 78.2, 71.4, 77.7, 62.7, 103.0, 76.0, 77.7, 71.4, 76.7, 69.5 and 105.1, 72.4, 74.2, 69.5, 66.7. The HMBC correlations between H-1′ and C-6, H-1′′ and C-6′, and H-1′′′ and C-2′ suggested the attachment position of the arabinosyl at C-8 and C-1′′ of glucose at C-6′ of glucose. Assignments of all groups of **3** were achieved by ^1^H-^1^H COSY, HSQC and HMBC ([Figure 2](#molecules-22-00828-f002){ref-type="fig"}). The absolute configuration of the glycosyls group of compound **3** was determined by GC analysis according to the same *t*~R~ at 16.8 min and 12.9 min with standard [d]{.smallcaps}-glucose and [l]{.smallcaps}-arabinose, respectively. From the above data and combined with the literature \[[@B26-molecules-22-00828],[@B27-molecules-22-00828]\], the structure of **3** was elucidated as (*Z*)-3-hexenyl *O*-β-[d]{.smallcaps}-glucopyranosyl-(1→2)-*O*-α-[l]{.smallcaps}-arabinopyranosyl-(1→6)-*O*-β-[d]{.smallcaps}-glucopyranoside, named Nicglycoside C.

2.2. Anti-Inflammatory Activity {#sec2dot2-molecules-22-00828}
-------------------------------

All compounds **1**--**18** were evaluated for their anti-inflammatory activities ([Table 2](#molecules-22-00828-t002){ref-type="table"}) inhibiting NO production of LPS-induced RAW 264.7 cells in vitro \[[@B27-molecules-22-00828]\]. NO, as a key pro-inflammatory mediator, could suppress inducible enzyme expression via inhibition of the mitogen-activated protein kinase pathway and nuclear translocation of critical transcription factors \[[@B28-molecules-22-00828],[@B29-molecules-22-00828]\]. The results suggested that the isolated compounds (**1**--**18**) possessed different degrees of activities in inhibiting NO production. For the compounds with the same mother nucleuses (**1**, **5**, **6**, **7**, **9**, **11**), compounds **7** and **11** showed weaker activities than others, which might be due to the moieties of rhamnose or trisaccharide. Compounds **8** and **10** showed weaker activities than other phenylethanoid glycosides, which might be ascribed to the hydroxy-substituted benzene rings.

3. Experimental Section {#sec3-molecules-22-00828}
=======================

3.1. General Experimental Procedures {#sec3dot1-molecules-22-00828}
------------------------------------

UV spectra were recorded on a Shimadzu UV-1601 instrument. HR-ESI-MS was performed on a Waters Xevo-TOF-MSTM.1D and 2D NMR spectra using a Bruker DPX 400 instrument with TMS as an internal standard. Preparative HPLC (Waters, Milford MA, USA, 515-2414) was performed on Sunfire (10 μm, 19 × 250 mm, Waters). ODS was obtained from YMC Company Ltd., Japan. Silica gel was used Qingdao Marine Chemical Ltd., Qingdao, China. All the solvents were of analytical grade and were purchased from Tianjinfuyu Company Ltd., Tianjin, China. ELISA reader was used from PerkinElmer, Waltham, MA, USA. The RAW 264.7 cells were from China Center for Type Culture Collection in Wuhan University, Hubei, China. DMEM was purchased from Corning, New York, NY, USA. The integrant biological agents were prepared, such as, MTT (Biotopped, Beijing, China), LPS (Sigma-Aldrich, St. Louis, MO, USA), DMSO (Sigma-Aldrich), Penicillin Streptomycin Solution (Corning, New York, NY, USA), Fetal bovine serum (Sijiqing, Hangzhou, China), NMMA (Sigma-Aldrich), Sulfanilic acid anhydrous (Tianli, Tianjin, China), *N*-(1-naphthyl) enylenediamine dihydrochloride (Damao, Tianjin, China), PBS (Biotopped).

3.2. Plant Material {#sec3dot2-molecules-22-00828}
-------------------

The fruits of *Nicandra physaloides* (L.) Gaertn were harvested from Harbin, Heilongjiang Province of China, in September 2014, which was identified by Prof. Ruifeng Fan of Heilongjiang University of Chinese Medicine. The voucher specimen (20140911) had been deposited at Heilongjiang University of Chinese Medicine.

3.3. Extration and Isolation {#sec3dot3-molecules-22-00828}
----------------------------

The dry fruits (15 kg) of *Nicandra physaloides* were extracted with 70% ethanol 3 times and the condensed crude (1167.2 g) was fractioned by AB-8 macroporous resin column chromatography and eluted with 10% EtOH (439.5 g), 30% EtOH (209.4 g) and 95% EtOH (176.1 g). The 10% EtOH elution (100.0 g) was concentrated and separated. Thirteen obtained fractions (Fr. I-XIII) were combined based on the TLCs. Fr. V was separated by ODS chromatography, eluted with H~2~O/MeOH (0:1 to 0:1), to afford Fr. V-1 to V-17. Fr. V-9 was subjected to ODS chromatography (H~2~O/MeOH, 1:0 to 0:1) to afford **3** (12 mg), **10** (8 mg) **12** (9 mg) and **15** (10 mg). Fr. V-16 was separated by ODS chromatography (H~2~O/MeOH, 1:0 to 0:1) to afford Fr. V-16-1 to V-16-10. Fr. V-16-2 was purified by to afford **2** (10 mg), **4** (8 mg), **5** (9 mg) and **17** (9 mg). Fr. VI was separated by ODS chromatography, eluted with H~2~O/MeOH (0:1 to 0:1), to afford Fr. VI-1 to VI-10. Fr. VI-5 were purified by preparative HPLC to afford **9** (11 mg), **13** (8 mg), **16** (12 mg) and **18** (10 mg). Fr. X was purified by ODS chromatography (H~2~O/MeOH, 1:0 to 0:1), to afford Fr. X-1 to X-15. Fr. X-11 and X-13 were repeatedly subjected to ODS chromatography (H~2~O/MeOH, 1:0 to 0:1) and then purified by preparative HPLC to afford **1** (12 mg), **6** (9 mg), **7** (10 mg), **8** (11 mg), **11** (9 mg) and **14** (9 mg), respectively.

Nicglycoside A (**1**). White amorphous powder. $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −8.9 (*c* = 1.30, MeOH); IR (KBr) 3435, 2921, 1750, 1260 cm^−1^; UV (MeOH) λ~max~ 212, 258, 271 nm; ^1^H- and ^13^C-NMR (MeOH, 400, 100 MHz) data, see [Table 1](#molecules-22-00828-t001){ref-type="table"}; HR-ESI-MS *m*/*z* 417.1755 \[M + H\]^+^ (calcd. for C~19~H~29~O~10~, 417.1761) ([Figures S1 and S2](#app1-molecules-22-00828){ref-type="app"}).

Nicglycoside B (**2**). White amorphous powder. $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −46.4 (*c* = 1.57, MeOH); IR (KBr) 1732, 1464, 1263, 710 cm^−1^; ^1^H- and ^13^C-NMR (MeOH, 400, 100 MHz) data, see [Table 1](#molecules-22-00828-t001){ref-type="table"}; HR-ESI-MS *m*/*z* 395.1901 \[M + H\]^+^ (calcd. for C~17~H~31~O~10~, 395.1917) ([Figures S3 and S4](#app1-molecules-22-00828){ref-type="app"}).

Nicglycoside C (**3**). White amorphous powder $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −51.8 (*c* = 1.60, MeOH); IR(KBr) 1730, 1458, 1260, 704 cm^−1^; ^1^H- and ^13^C-NMR (MeOH, 400, 100MHz) data, see [Table 1](#molecules-22-00828-t001){ref-type="table"}; HR-ESI-MS *m*/*z* 557.2419 \[M + H\]^+^ (calcd. for C~23~H~41~O~15~, 557.2445) ([Figures S5 and S6](#app1-molecules-22-00828){ref-type="app"}).

3.4. Acid Hydrolysis and GC Analysis {#sec3dot4-molecules-22-00828}
------------------------------------

The isolated glycosides (**1**--**18**) (2.0 mg) were refluxed with 2 mL H~2~O and 2 N aqueous 1 mL HCl for water bath (3 h). Then, the reaction mixtures were extracted with ethyl acetate for 3 times (5 mL). The aqueous layer was neutralized and evaporated with MeOH and then dissolved in anhydrous pyridine (5 mL) and treated with [l]{.smallcaps}-cysteine methyl ester hydrochloride (1.5 mg). After being stirred for 1 h at 60 °C, the mixture was added into 150 μL of HMDS--TMCS (3:1) and then stirred for another 30 min at 60 °C. The supernatant was concentrated under N~2~ stream after being centrifuged off. The residue was partitioned between *n*-hexane and H~2~O (0.1 mL each), and the hexane layer (1 μL) was analyzed by GC \[[@B30-molecules-22-00828],[@B31-molecules-22-00828]\], respectively. The configurations of [d]{.smallcaps}-glucose for compounds **3**--**18** were determined by the same *t*~R~ of standard [d]{.smallcaps}-glucose (*t*~R~ = 16.8 min), [l]{.smallcaps}-arabinose for compounds **1**--**5**, **16**, **18** (*t*~R~ = 12.9 min), [d]{.smallcaps}-galactose for compound **1**--**2** (*t*~R~ = 32.5 min), and [l]{.smallcaps}-rhamnose for compound **7**, **10** (*t*~R~ = 14.8 min).

3.5. Anti-Inflammatory Assays {#sec3dot5-molecules-22-00828}
-----------------------------

RAW 264.7 cells were cultivated at densities of 5 × 10^5^ cell/wells in 96-well for 24 h, then discarded the supernatants and stimulated by LPS (100 μL, 1 μg/mL) to generate NO for cultivating 24 h. Following incubation of the demonstrated time, the amount of sable nitrite, the end product of NO generation by activated cells, were determined by a modification of the Griess reaction \[[@B32-molecules-22-00828],[@B33-molecules-22-00828]\]. The cells were treated with 100 μL of the compounds by the final concentration of 5, 25, 50, 100 and 200 μg/mL. Briefly, 100 μL of culture supernatants from control or stimulated macrophages were transferred to 96-well plates. Supernatants were mixed with 50 μL of 1% sulfanilic acid anhydrous in 85% phosphoric acid, incubated for 10 min at room temperature, shielded from light, followed by 50 μL of 1 mg/mL *N*-(1-naphthyl) ethylenediamine dihydrochloride for 10 min incubation in light proof. The absorbance was measured at 540 nm using an ELISA reader, and nitrite concentration was determined by comparison with a sodium nitrite standard curve. NMMA was used as a positive control. No isolates did showed an effect on the assay systems with the final concentration 0.2 (*v*/*v*) in DMSO and the MTT assay revealed no significant cytotoxic effects (over 90% cells survival) on cells treated with above compounds at concentrations up to 200 μg/mL.

4. Conclusions {#sec4-molecules-22-00828}
==============

As described in the introduction, *Nicandra physaloides* possessed many kinds of bioactivities such as heat-clearing, detoxifying, antipyresis, and anti-inflammation, and was applied to the treatments of rheumatoid arthritis, and so on. This study obtained the 18 glycosides compounds from the *Nicandra physaloides* fruits, including phenyl-glycosides and fat glycosides. Meanwhile, many researchers have reported that the aromatic glycosides and phenyl-glycosides show significant anti-inflammatory activities \[[@B34-molecules-22-00828],[@B35-molecules-22-00828],[@B36-molecules-22-00828],[@B37-molecules-22-00828]\]. Thus, the anti-inflammatory activities of the compounds were evaluated, some of which showed significant activities. These results indicated that these glycosides compounds could be the pharmacodynamic material basis for anti-inflammation from the *Nicandra physaloides* fruits, and played important roles in the treatments of inflammatory diseases such as rheumatoid arthritis, nasosinusitis, influenza, urinary tract infection, sore and furuncle. The systematic studies on the composition in this manuscript will be the foundations and references of further research. We have made contributions to discovering active ingredients and leading compounds and provided experimental and scientific basis of drug design and drug discovery of the *Nicandra physaloides*.
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molecules-22-00828-t001_Table 1

###### 

^1^H- and ^13^C-NMR Data of **1**--**3** (CD~3~OD).

  No.   1       2                    3                                      
  ----- ------- -------------------- ------- ---------------------- ------- ----------------------
  1     140.2                        14.6    0.96 (3H, t, 7.6)      14.7    0.97 (3H, t, 7.6)
  2     129.4   7.24 overlap         21.6    2.07 (2H, m)           21.6    2.08 (2H, m)
  3     130.0   7.24 overlap         134.5   5.42 (m)               134.5   5.42 (m)
  4     127.2   7.16 (m)             125.9   5.42 (m)               126.0   5.42 (m)
  5     130.0   7.24 overlap         28.8    2.37 (2H, m)           28.8    2.38 (2H, m)
  6     129.4   7.24 overlap         70.6    3.52 overlap           70.6    3.54 overlap
                                             3.84 overlap                   3.85 overlap
  7     37.3    2.92 (t, 7.4)                                               
  8     71.8    3.74 overlap                                                
                4.07 overlap                                                
  1′    102.0   4.65 (d, 7.9)        102.0   4.61 (d, 8.0)          105.0   4.59 (d, 7.8)
  2′    72.3    3.34 overlap         72.3    3.51 (m)               83.0    3.20--3.80 (m)
  3′    72.8    4.04 (m)             72.8    4.05 (m)               78.2    3.20--3.80 (m)
  4′    68.8    3.55 (m)             68.8    3.55 (m)               71.4    3.20--3.80 (m)
  5′    74.5    3.83 (m)             74.4    3.82 (m)               77.7    3.20--3.80 (m)
  6′    69.8    4.09 overlap         69.8    4.06 (dd, 11.2, 2.0)   69.5    4.09 (dd, 11.2, 1.9)
                3.70 overlap                 3.72 (dd, 11.2, 5.0)           3.70 (dd, 11.4, 5.1)
  1″    105.2   4.29 (d, 6.7)        105.2   4.30 (d, 6.7)          105.1   4.30 (d, 6.7)
  2″    72.4    3.57 (m)             72.4    3.59 (m)               72.4    3.20--3.80 (m)
  3″    74.2    3.47 (m)             74.2    3.50 (m)               74.2    3.20--3.80 (m)
  4″    69.5    3.78 (m)             69.5    3.80 (m)               69.5    3.20--3.80 (m)
  5″    66.7    3.50 (dd,12.5,3.2)   66.7    3.52 overlap           66.7    3.51 overlap
                3.85 (dd,12.5,2.0)           3.87 overlap                   3.87 overlap
  1″′                                                               103.0   4.43 (d, 7.6)
  2″′                                                               76.0    3.20--3.80 (m)
  3″′                                                               77.7    3.20--3.80 (m)
  4″′                                                               71.4    3.20--3.80 (m)
  5″′                                                               76.7    3.20--3.80 (m)
  6″′                                                               62.7    3.52 overlap
                                                                            3.87 overlap

molecules-22-00828-t002_Table 2

###### 

Inhibitory on NO production in LPS-induced RAW 264.7 cells of compounds **1**--**18**.

  Compounds        IC~50~ (μM)   Compounds         IC~50~ (μM)
  ---------------- ------------- ----------------- -------------
  NMMA ^b^         19.6 ± 2.4                      
  Compound **1**   31.1 ± 3.5    Compound **10**   \>50
  Compound **2**   32.9 ± 5.6    Compound **11**   41.7 ± 7.6
  Compound **3**   41.2 ± 4.1    Compound **12**   29.8 ± 5.7
  Compound **4**   30.2 ± 4.7    Compound **13**   36.6 ± 3.9
  Compound **5**   26.9 ± 5.1    Compound **14**   \>50
  Compound **6**   37.5 ± 4.7    Compound **15**   25.1 ± 4.4
  Compound **7**   41.2 ± 6.6    Compound **16**   38.9 ± 5.9
  Compound **8**   \>50          Compound **17**   33.4 ± 2.7
  Compound **9**   34.8 ± 6.3    Compound **18**   31.4 ± 4.2

IC~50~ was defined as the concentration that resulted in a 50% inhibition on NO production. The IC~50~ greater than 50 μM was deemed inactive. ^b^ Positive control.
